PTEN is a phosphatase which metabolises PIP 3, the lipid product of PI 3-Kinase, directly
opposing the activation of the oncogenic PI3K/AKT/mTOR signalling network. Accordingly …

With the rapid development of new technologies, including artificial intelligence and genome
sequencing, radiogenomics has emerged as a state-of-the-art science in the field of …

Sex-steroid hormones have been investigated for decades for their oncogenic properties in
hormone-dependent cancers. The increasing body of knowledge on the biological actions of …

In tumors, somatic mutations of the PTEN suppressor gene are associated with advanced
disease, chemotherapy resistance, and poor survival. PTEN loss of function may occur by …

The androgen inactivating UGT2B28 pathway emerges as a predictor of progression in
prostate cancer (PCa). However, the clinical significance of UGT2B28 tumoral expression …

Sustained pro-proliferative signaling is one of the hallmarks of cancer. Although it is
generally understood that the oncogenic signaling pathways are overactivated, or at least …

Prostate cancer (PCa) cells rely on the androgen receptor (AR) signaling axis to reprogram
metabolism to sustain aberrant proliferation. Whether additional transcription factors …

Many transcription factors (TFs) function as tumor suppressor genes with heterozygous
phenotypes, yet haploinsufficiency generally has an underappreciated role in neoplasia …

The CRISPR-Cas9 system is a powerful tool for studying gene functions and holds potential
for disease treatment. However, precise genome editing requires thorough assessments to …

Cancer cells are more vulnerable to abnormal redox fluctuations due to their imbalanced
antioxidant system, where cell surface receptors sense stress and trigger intracellular signal …